Christina Carruthers

Christina Carruthers has a strong background in the pharmaceutical and biotech industry, with experience in various leadership roles. Christina is currently the Vice President of Target Strategy and Early Development at HTG Molecular Diagnostics. Prior to this, they worked at Moderna as the Therapeutic Area Lead for Rare Disease. From 2019 to 2021, they served as the Scientific Director and Nonclinical Safety Lead at The Janssen Pharmaceutical Companies of Johnson & Johnson. Before that, they held the position of Director of Preclinical Development and Operations at SCYNEXIS, Inc. Christina also gained valuable experience at Allergan, where they served as the Director of Toxicology and held various other roles, including Principal Scientist. Christina began their career as a Post Doctoral Fellow at the National Institute of Environmental Health Sciences. Overall, Christina's work experience reflects a consistent trajectory of increasing responsibility and expertise in the field of pharmaceutical research and development.

Christina Carruthers holds a PhD from Bowling Green State University and a BS from Central Connecticut State University. The start and end years of their educational pursuits are not provided.